Dr. Thomas Wilckens
CEO InnVentis Ltd.
Thomas Wilckens is an MD and serial entrepreneur. His current focus is venture InnVentis Ltd (Israel) and the convergence of multi-omics technologies with real-world clinical data and machine learning to enable PRECISION MEDICINE, Thomas is also the founder of the LinkedIn group PRECISION MEDICINE Insight an Associate at deep innovation GmbH, a boutique consultancy headed by the fmr. Head Group R&D Vodafone. Before joining deep innovation, he founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University before heading off to basic research as a scholar of the Max-Planck Society and the Max-Kade Foundation, NY. He held several postdoc positions at leading academic institutions before becoming an entrepreneur. Aside from his work in Precision Medicine he developed a novel concept for value creation in research intensive industries; i.e. “Symbiotic Innovation”. With regard to this project Thomas is an associate at the GLORAD Research Center for Global R&D Management St. Gallen/Shanghai. Thomas is convinced that we will see a disruption of current diagnostics & therapeutic concepts and related business models. This paradigm shift will be induced by the advent of even greater communication and computing capabilities in concert with progress in omics and sensor technologies; i.e. Precision Medicine will ultimately be supported by algorithms for prevention, diagnostics and therapeutic decision making and become available anywhere 24/7.
Yves A. Lussier, MD, FACMI
Associate Vice President for Data Science, The University of Arizona Health Sciences, Director, Center for Biomedical Informatics and Biostatistics
Dr. Lussier is the Associate Vice President for Data Science and Chief Knowledge Officer for The University of Arizona Health Sciences. He also currently serves as the Director of the Center for Biomedical Informatics and Biostatistics, Associate Director for Cancer Informatics and Precision Health, and the Associate Director for Informatics of the BIO5 Institute at The University of Arizona. He is an internationally renowned physician-scientist and a pioneer of the field of translational bioinformatics. A practitioner of medicine for over seventeen years, he has been a member of the administrative board of four hospitals and published over 150 scientific papers and books chapters. He previously served as Director of three NIH-Funded bioinformatics cores at Columbia University and the University of Chicago. Dr. Lussier co-founded Purkinje, the first tablet-based electronic medical records anchored on the first commercial ontology, as well as developed and implemented Vigilens, the first ontology-anchored clinical event monitor that has been in operation at the New York Presbyterian Hospital of Columbia University since 2002. Leveraging bio-ontologies, he has pioneered and enabled clinical interpretation of personal transcriptomes dynamics between two samples, thus abrogating cohort-based statistics requirements
Dr. Lussier strongly believes that since every patient is a unique individual with a wide range of variability in genes, environment, and lifestyle, it is necessary to devise custom strategies when designing treatment methods. In his role as the Director of the Center for Biomedical Informatics and Biostatistics (CB2), he leads the initiative to build a data-driven learning health system, advance precision medicine analytics, and translate Big Data science and genomic discoveries to clinical care for The University of Arizona’s research and clinical communities. In addition to his role with CB2, his research group conducts hypothesis-driven translational research in biomedical informatics using clinical and genomic big data, knowledge technologies, and networks to better understand the pathology, progression, and treatment for diseases at the individual patient level. They are developing scalable computational data science technologies to efficiently and affordably heal humanity – one person at a time.
Lynn G. Dressler, Dr.P.H.
Director of Personalized Medicine, Fullerton Genetics Center and Mission SECU Cancer Center, Mission Health.
Dr. Dressler joined Mission Health, in February 2013, to develop and direct the Personalized Medicine and Pharmacogenomics Program. Formerly a faculty member in the Schools of Medicine and Pharmacy at the University of North Carolina at Chapel Hill, and a founding member of the UNC Institute for Pharmacogenomics and Individualized Therapy, Dressler’s 30 year career spans translational laboratory research in cancer, health policy research and the ethical ,legal, and social implications (ELSI) of genomic medicine. Dressler holds a Master’s in Experimental Pathology, a doctorate in Health Policy and completed a fellowship in ELSI research. At UNC, her laboratory conducted the research study that directly led to the FDA approval of the HER2 FISH assay (PathVYsion ™), one of the first pharmacogenomic tests in solid tumors. In North Carolina, nearly 10 years prior to GINA, (Genetic Information Non Discrimination Act, Federal Statute), Dressler worked with the North Carolina General Assembly to pass a law to prohibit discrimination by employers and health insurance providers on the basis of an individual’s genetic information. She has over 100 publications in related fields.
Working closely with NIH/NCI/NHGRI, Dressler has served in many leadership roles (External Advisor to The Cancer Genome Atlas Study (TCGA); NCI caHUB ethics working group, co- Chair Correlative Sciences Committee of the Cancer and Leukemia Group B). She currently serves as a member of the Clinical Pharmacogenomics Implementation Committee (CPIC); an affiliate member of the NIH Consortium IGNITE, and a guest member of the Institute of Medicine’s Roundtable on Translating Genomic Findings to Improve Population Health.
Dr. Paul R. Billings, M.D., Ph.D, FACP, FACMG
Chair, Biological Dynamics, Inc.
Dr. Paul R. Billings is a board-certified internist and clinical geneticist. He is a Principal in the consultancy, the Bethesda Group and is Chairman of both PlumCare, LLc and Biological Dynamics, Inc. Dr. Billings has held appointments at Harvard University, UCSF, Stanford University and UCB. He is a co-founder and CMO of Omicia, Inc.
Atul Butte, MD, PhD
Director of the Institute of Computational Health Sciences
Atul Butte, MD, PhD is the inaugural Director of the Institute of Computational Health Sciences (ichs.ucsf.edu) at the University of California, San Francisco, and a Distinguished Professor of Pediatrics. Dr. Butte is also the Executive Director for Clinical Informatics across the six University of California Medical Schools and Medical Centers. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children’s Hospital Boston, then received his PhD from Harvard Medical School and MIT. Dr. Butte has authored nearly 200 publications, with research repeatedly featured in Wired Magazine, the New York Times, and the Wall Street Journal. Dr. Butte was elected into the National Academy of Medicine in 2015, and in 2013, he was recognized by the White House as an Open Science Champion of Change for promoting science through publicly available data. Dr. Butte is also a founder of three investor-backed data-driven companies: Personalis, providing clinical interpretation of whole genome sequences, Carmenta (acquired by Progenity), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs through open molecular data. Dr. Butte is a principal investigator of three major programs: the California Initiative to Advance Precision Medicine; the California Precision Medicine Consortium, helping recruit tens of thousands of participants into President Obama’s Precision Medicine Initiative; and ImmPort, the clinical and molecular data repository for the National Institute of Allergy and Infectious Diseases.
James N. Czaban
Partner & Chairman of the FDA and Medical Products Regulatory Practice Group at DLA Piper LLP
James N. Czaban is a Partner and the Chairman of the FDA and Medical Products Regulatory Practice Group at the international law firm DLA Piper LLP, in Washington, D.C. In nearly 25 years of private practice, Jim has focused on counseling pharmaceutical, medical device and diagnostic, and other life sciences clients on a broad range of complex regulatory strategies and compliance matters, and regularly represents such clients in legal, public policy, and enforcement matters before the FDA, other administrative agencies, and in the federal courts. Jim has been deeply involved in the law and regulation of Precision Medicine since mapping of the human genome was completed more than 15 years ago. In 2001, Mr. Czaban published one of the first scholarly legal analyses of FDA’s potential approaches to regulating Precision Medicine, titled “Pharmacogenomics: The Uncertain Path to Deciphering the Regulatory Genome,” and more recently, published a comprehensive analysis of FDA’s efforts to tighten its control over the development and commercialization of Precision Medicine technologies, in the article “Promotion of Precision Medicine Under Imprecise Rules” (FDLI 2016). Mr. Czaban is a recipient of the Burton Award for Legal Excellence (2010) for his groundbreaking work involving FDA regulation of, and patent litigation involving, the emerging field of biosimilar products. He earned his undergraduate degree from the University of California, Berkeley (1988), and his law degree from the University of Virginia School of Law (1992).
Ron Mazumder, PhD, MBA
Head of Companion Diagnostics, Genentech, Inc.
Abhijit “Ron” Mazumder obtained his B.A. from The Johns Hopkins University, his PhD from the University of Maryland, and his MBA from Lehigh University. After working at several biotechs, he joined Johnson & Johnson in 2003 and led molecular diagnostics programs and biomarker partnerships. In 2008, he joined Merck as a Senior Director and Biomarker Leader in external discovery, where he was responsible for the development and execution of (pharmacodynamic and predictive) biomarker plans in support of lead optimization and clinical candidates, and also managed external collaborations and technology evaluations. Ron rejoined Johnson & Johnson in 2010 and led the development of companion and complementary diagnostics across the therapeutic pipeline. In October 2016, he joined Genentech where he leads a team developing companion and complementary diagnostics across Genentech’s immune-oncology, hematology/oncology and non-oncology programs.
Emanuel Petricoin III, PhD
University Professor, Co-Director Center for Applied Proteomics and Molecular Medicine, George Mason University
Dr. Emanuel F Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program and a Senior Investigator within the Center for Biologics Evaluation and Research at the FDA from 1993-2005. Dr. Petricoin received his PhD in Microbiology from the University of Maryland in 1990. The focus of the CAPMM is the invention and use of proteomics technologies for personalized therapy, molecular diagnostics and biomarker discovery. He is a co-founder of 4 life science companies, including 2 precision medicine companies: Theranostics Health, Inc. and Perthera, Inc. located in McClean VA, where is a co-founder and Chief Science Officer. He is a co-inventor on 40 filed and published patents, and has authored over 360 peer-reviewed publications and invited reviews. He has authored over 45 book chapters, is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention and on the editorial board of JCO Precision Oncology, Proteomics, Biomedical Microdevices, Proteomics-Clinical Applications, Proteomics-Protocols, Molecular, Carcinogenesis, Journal of Personalized Medicine and Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO). He has received numerous awards including the University Professorship at George Mason University, the NIH Director’s Award, FDA Distinguished Scientist Award, 2015 Innovator of the Year Award, GAP50 Top Virginia Entrepreneurs, Nifty 50 Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award and is s Kentucky Colonel. He is the faculty representative to the George Mason University Research Foundation.
Dr. George Poste
Professor of Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University
Dr. Poste is currently the Professor of Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University. This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision medicine.
He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences and Scientific Advisory Boards at the University of Michigan, Synthetic Genomics and Haplogen GmbH.
He is a Fellow of the U.K. Royal Society, the Royal College of Pathologists and U.K. Academy of Medicine, Member, Council for Foreign Relations, and Institute of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.
Lee S. Schwartzberg, M.D., F.A.C.P.
Executive Director and Chief Medical Officer, the West Cancer Center
Lee S. Schwartzberg, M.D., F.A.C.P. is the Executive Director and chief medical officer of the West Cancer Center. He is a Professor of Medicine and Chief, Division of Hematology/Oncology at The University of Tennessee Health Science Center. Dr. Schwartzberg is board certified in internal medicine, hematology, and medical oncology. He also serves as President /CMO for Vector Oncology, an oncology specific SMO/CRO. He was the founding editor-in-chief of the journal Community Oncology and serves as the editor-in-chief of the website Practice Update Oncology. He serves on the editorial board of the Journal of Supportive Oncology and the ASCO post and is a reviewer for many journals including the New England Journal of Medicine and the Journal of Clinical Oncology. He also serves on the board of directors for the National Comprehensive Cancer Network. Dr. Schwartzberg’s major research interests are new therapeutic approaches to breast cancer, targeted therapy and supportive care having published over 150 research papers. He maintains a private practice in medical oncology focusing on breast cancer.
Nephi Walton MD, MS –
Pediatrician / Genetics Fellow at Washington University School of Medicine, Cofounder BrainSpin
Dr. Nephi Walton earned his MD from the University of Utah School of Medicine and an MS in Medical Informatics from the University of Utah Department of Biomedical Informatics where he was a National Library of Medicine fellow. His Masters work was focused on data mining and predictive analytics of viral epidemics and their impact on hospitals. He was the winner of the 2009 AMIA Data Mining Competition and has published papers and co-authored books on data mining and predictive analytics. His work has included several interactive medical education products. He founded a company called Brainspin that continues this work and has won awards for innovative design in this area. He is currently a combined Pediatrics/Genetics fellow at Washington University where he is pursuing several research interests including the application of predictive analytics models to genomic data and integration of genomic data into the medical record.
Paul Langley, PhD
Adjunct Professor, College of Pharmacy, University of Minnesota, Director, Maimon Research LLC
Dr Langley is a health economist with over 30 years’ experience in consulting, academia and the pharmaceutical industry. The focus of Dr Langley’s academic and consulting activities is on the evidence base to support clinical and formulary decisions. Over the past 15 years Dr Langley has advised health care systems in the US, Australia and the European Union on the need for processes to be put in place to ensure that claims made for products and devices, both clinical and cost-effective, meet the standards of normal science for evaluation and replication. Dr Langley has published widely and at present is directing a program at the University of Minnesota on formulary evaluation with particular emphasis on personalized and precision medicine claims. The critical feature is the presence of an interactive evidence base that supports at risk target populations in the long-term.